Thanks for logging in.

You can now click/tap WATCH to start the live stream.

Thanks for logging in.

You can now click/tap LISTEN to start the live stream.

Thanks for logging in.

You can now click/tap LATEST NEWS to start the live stream.

LISTEN
Watch
on air now

Create a 2GB account today!

You can now log in once to listen live, watch live, join competitions, enjoy exclusive 2GB content and other benefits.


Joining is free and easy.

You will soon need to register to keep streaming 2GB online. Register an account or skip for now to do it later.

Advertisement
Advertisement
Advertisement

Ovarian and prostate cancer developments give ‘hope for the future’

Article image for Ovarian and prostate cancer developments give ‘hope for the future’

Groundbreaking ovarian cancer drug lynparza will soon be available much earlier in patients’ cancer journey under the Pharmaceutical Benefits Scheme.

Manufacturer AstraZeneca announced the drug’s PBS listing will be expanded from November 1.

Pink Hope founder and CEO Krystal Barter told Jim Wilson ovarian cancer is a “silent killer”, and the wider availability of lynparza is an important milestone.

“I think it’s really important to know that there is hope for the future, to know that there’s incredible research happening, and science … will give future generations better options.”

Click PLAY below to hear the full interview

Meanwhile a free, three-minute online risk assessment tool is proving useful in identifying potential prostate cancer patients.

Maxwell Plus founder Dr Elliott Smith told Jim Wilson it was previously more difficult to tell the difference between aggressive and slow-moving cancers, causing men confusion.

The free quiz gives men a clear picture of their risk, to help them decide whether to take further action.

“At the end of the day, nothing other than a test is going to give you the ultimate answer.”

Click PLAY below to hear the full interview

Image: Getty

 

Jim Wilson
Advertisement